Harnessing modern technologies like metabonomics will ‘provide the answers’ to questions about how the gut microflora affect human health, says the scientist who co-coined the term ‘prebiotic’.

Professor Glenn Gibson has spent the majority of his professional career at the business end of the digestive tract. He is currently Professor of Food Microbial Sciences at the University of Reading in the UK.

Since the coining of the term ‘prebiotic’ in a paper in 1995, Prof Gibson has continued to lead research in the field. Talking to NutraIngredients-USA, Gibson professed his excitement over the potential of new technologies, and metabonomics in particular, to “provide the answers” to the subjects unanswered questions.

Metabonomics is part of the bigger subject of nutrigenomics, which includes transcriptomics and proteomics: In other words, changes to messenger RNA (transcriptomics) and the corresponding proteins (proteomics) control the transport of certain nutrients and metabolites (metabonomics) in the biochemical pathway.

“I do think going from molecular to metabolic is a sea change.”

“We’re on the verge of understanding the role of this big organ [the gut] on health and disease,” he said. Gut health is no longer just about how regular your bowel movements are, but has reported implications for immunity, brain health, and weight gain.

“I’m not amazed by the potential health benefits of modifying gut microflora because of the sheer numbers of cells involved,” said Prof Gibson. “Bacteria will come to play a major role in health and wellness.”

A long and winding road

Prof Gibson’s PhD was in the field of marine and estuarine sediments at the University of Dundee in Scotland, and he’s quick to note that sediments and the human gut have more in common than you’d think: Both contain bacteria that can produce hydrogen sulfide (H2S) – a noxious gas that smells like rotten eggs.

His interest in H2S-producing bacteria led him to look at how these may promote human conditions such as ulcerative colitis.

Probiotics were the obvious next step in his research, and attempts to change the microbial populations to produce health benefits.

Belgian sugar company Orafti (now Beneo) then came calling with an ingredient called inulin, funding a PhD student under Prof Gibson’s guidance.

Prof Gibson’s interactions with Orafti introduced him to Marcel Roberfroid from the Catholic University of Louvain, who was working as a consultant to the Belgian company.

Working together in a hotel room near Victoria train station in London, Roberfroid and Gibson produced a landmark paper in the Journal of Nutrition and introduction of the concept of ‘prebiotics’ (Vol. 125, pp. 1401-1412).

The same paper also introduced the term ‘synbiotic’, which is a synergistic combination of prebiotic fibers and probiotic bacterial strains.

Leap forward

The early Orafti-sponsored project was time consuming, and involved hours of culturing bacteria in Petri dishes. The advent of molecular biology allowed the research, which had been ‘stagnating’, to leap forward.

“This was a big step,” said Gibson, “and allowed us to do volunteer trials.”

Even as the quantity of data grows and our understanding more complex, moves are being made to simplify the subject: An international team of researchers recently reported in Nature that microflora in our guts may fit into one of three distinct groups, called enterotypes: Bacteroides, Prevotella and Ruminococcus.

Prof Gibson is quick to point out that such a study was based on data from only 22 people and notes that Bifidobacteria were not shown. “What this paper did show was the value of high throughput sequencing,” he said.

Obesity

An interesting development in recent years stems from a study from the lab of Jeffrey Gordon at the University of Washington in St Louis. In articles published in Nature in December 2006 (Vol. 444, pp. 1022-1023, 1027-1031) Dr Gordon and his team reported that microbial populations in the gut are different between obese and lean people, and that when the obese people lost weight their microflora reverted back to that observed in a lean person, suggesting that obesity may have a microbial component.

“By playing with the gut microflora, can we drag people from obese to lean?” asks Prof Gibson. “Obesity is related to genetics, the diet, and exercise… and there are gut flora difference. We can do something about gut flora, and this can affect appetite, it can affect the calories extracted from food.”

Prof Gibson is quick to add that the changes to gut microflora produced by prebiotics “only last as long as you take the intervention”. In other words, stop taking the prebiotics and, within about a week, the gut microflora returns to what it was before you started taking it.

This represents an opportunity for the food and nutrition industries – “you can put prebiotics into food people eat anyway”.

The EFSA issue

The science appears impressive, and the potential immense, but mention EFSA and Prof Gibson’s tone changes. The prebiotic pioneer has watched while the European Food Safety Authority (EFSA) released negative opinion after negative opinion for pre- and probiotics.

The 1-log pathogen reduction rule (in order to produce an effect against pathogenic bacteria, the intervention must display a reduction in population of 1-log) is “nonsense”, he says, “because it doesn’t take into account of starting populations.

“If one of my undergraduates made such a statement, they’d fail.

“If you have 10 million Campylobacter, you have food poisoning. If you then reduce this by 1-log to one million you’d still have food poisoning. Where’s the benefit?”

Bifido-bashing

EFSA’s dismissal that a promotion of Bifidobacteria populations does not relate to a health benefit is “rubbish”, said Prof Gibson.

“I could cite hundreds of studies that contradict this.

“The literature is overwhelmingly in favor of probiotics and prebiotics.”

So how does he rationalize EFSA’s decisions? He doesn’t: “I’m very, very puzzled”.

“People who make good prebiotics and do the work in building the science will walk [away from Europe],” he predicts. “They’ll go to Asia and America where the legislation is hard and fair and clear.”

Comments from EFSA suggest that the science is not developed enough to answer all of their questions, but Prof Gibson dismisses suggestions that health claims came too soon for pro- and prebiotics, and he points eastward for evidence: “The Japanese have their act together,” he says, “and they have 100s of foods with FOSHU status, and these include prebiotics and probiotics.”

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below:

2 comments(Comments are now closed)

Delatee - Back up your claims.

It is not in the practice of respectable scientists to bash others without documentation of your claims. Please cite supporting evidence for all of your claims.

Report abuse

Posted by GLC19 May 2011 | 17h142011-05-19T17:14:45Z

The Prebiotic pioneer.....

Sorry but I have to laugh!
1:- Monica Bryant and Myself (1985), we invented the term PROBIOTIC.
2:-In 1988, I had a patent for the treatment of Immunity with lactic bacteria and Colonic strains.
3:-In 1989, I took a L.reuteri strain from Dundee, a strain that Dundee could not even ferment.
4:-In 1989, when I was attacked by the pharmaceutical establishment, the so-called pionner declared that "lactic bacteria are just powder yogurt!"
5:-What is called "prebiotic" is just revalorized food scraps. Studied financed by the same food scrap industry has little value.
So, the "pionner" just jumped into the train, I call this a scientific kidnapping.
Yves Delatte

Report abuse

Posted by yves Delatte18 May 2011 | 07h482011-05-18T07:48:46Z

Related products

On-Demand Supplier Webinar

27-Jan-2015 - A non GMO positioning is gaining in importance in the marketplace, experts agree. Gaining a non GMO certification in supplements is tricky, though, as so many products have multiple ingredients and manufacturers may find it difficult to certify many common...

On-Demand Supplier Webinar

12-Nov-2014 -
What’s hot in dietary supplements?
What’s the next break-out ingredient?
Can sports nutrition continue to flex its muscle?
What’s happening with online retailers?
Are there any regulatory hotspots to watch for?
Where’s the potential in foreign markets?
What next for GMOs and ‘natural’?
What’s on the horizon...

Video

10-Feb-2015 - Magnesium is needed for over 360 biochemical functions in the body, from energy production to sleep. But it has little benefit if the body cannot absorb or tolerate it. See what Albion’s scientists discovered when they bound magnesium to amino acids such as glycine,...

Technical / white paper

01-Jan-2015 - Increasing studies support the importance of reduced glycemic response within our diet. Inulin has proven effects on reducing glycemic response while replacing sugars. In fact, EFSA has acknowledged that inulin has an effect on glycemic response.

Technical / white paper

18-Feb-2015 - Gone are the days when the Brand Owner or Own Label Distributor could abdicate the responsibility for the quality of their products to the Contract Manufacturing Organization. This is exactly why Gemini Pharmaceuticals
developed a Quality Partnership Program. With over...

Clinical study

01-Feb-2015 - Cyactiv™, a brilliant “blue antioxidant” provides a new path to a healthy inflammation response allowing for an active lifestyle and overall wellness. Cyactiv is a natural, GRAS-designated microalgae extract, which is clinically proven to reduce physical discomfort in joints and...

Research study

22-Jan-2015 - Magnesium is required by over 360 biochemical functions in the body, from energy production to sleep. But, it has little benefit if the body cannot tolerate or absorb it. Learn which forms of magnesium provide the greatest absorption, stability and tolerance. Find out...

Application note

02-Feb-2015 - Marinova is an Australian biotechnology company dedicated to the research, development and manufacture of fucoidan extracts - complex sulfated polysaccharides derived from brown seaweed. Fucoidans are safe, natural compounds with wide ranging bioactivities that make them particularly beneficial in dietary...

Technical / white paper

01-Mar-2015 - InterHealth offers weight-loss ingredient brands backed by published clinical research and extensive quality testing per GLP guidelines. We know that your priority is selecting the finest weight loss ingredients on the market for your customers. You need a partner who...

Technical / white paper

16-Feb-2015 - Half of US consumers surveyed say the fiber level of a food product influences their purchase decision. This is especially true for younger people. The majority of consumers surveyed were interested in healthy, sugar-reduced food applications.

Technical / white paper

03-Feb-2015 - InterHealth’s weight-loss ingredients—Meratrim®, Super CitriMax®, 7-Keto® and LOWAT®—are backed by weight management clinical research. Thinking about formulating a non-stimulant based product? How about an appetite suppressor or an adiponectin regulator? We will collaborate with you determine which one of our...

Data sheet

22-Jan-2015 - Slimaluma is the only Caralluma Fimbriata extract clinically proven to support healthy weight management. This patented, standardized extract has a dual mechanism of action: (1) appetite suppression and (2) abdominal fat reduction. Several studies have been conducted on Slimaluma, including...

Technical / white paper

19-Jan-2015 - Scientists now understand that high-calorie, processed foods contribute to impaired glucose tolerance, which affects blood glucose metabolism, and may lie at the heart of the growing overweight population. Emerging science shows the promise of Salacia oblonga, a traditionally used herbal...

Clinical study

01-Feb-2014 - In the double-blind study, 123 participants were randomly selected to take IQP-PV-101, (Phase 2® white kidney bean extract) or a placebo. Participants taking Phase 2 lost an average of 7 pounds at the conclusion of 12 weeks and lost significantly more body...